James P Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA; Division of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Department of Biostatistics and Computational Biology, University of Rochester, Rochester, NY, USA.
Exp Gerontol. 2023 Jun 15;177:112185. doi: 10.1016/j.exger.2023.112185. Epub 2023 Apr 29.
BACKGROUND: Elevated markers of inflammation, such as interleukin-6 (IL-6), are associated with aging, cancer, and functional decline. We assessed the association of pre-diagnosis IL-6 levels with post-diagnosis functional trajectories among older adults with cancer. Black and White participants experience different social structures, therefore we sought to understand whether these associations differ between Black and White participants. METHODS: We conducted secondary analysis of the Health Aging, Body, and Composition (ABC) prospective longitudinal cohort study. Participants were recruited from 4/1997 to 6/1998. We included 179 participants with a new cancer diagnosis and IL-6 level measured within 2 years before diagnosis. Primary endpoint was functional measures (self-reported ability to walk 1/4, 20-meter gait speed). Nonparametric longitudinal models were used to cluster the trajectories; multinomial and logistic regressions to model associations. FINDINGS: Mean age was 74 (SD 2.9); 36 % identified as Black. For self-reported functional status, we identified 3 clusters: high stable, decline, low stable. For gait speed, we identified 2 clusters: resilient, decline. The relationship between cluster trajectory and IL-6 was different between Black and White participants (p for interaction<0.05). For gait speed, among White participants, a greater log IL-6 level was associated with greater odds of being in the decline vs. resilient cluster [Adjusted Odds Ratio (AOR): 4.31, 95 % CI: 1.43, 17.46]. Among Black participants, a greater log IL-6 levels were associated with lower odds of being in the decline vs. resilient cluster (AOR: 0.49, 95 % CI: 0.10, 2.08). Directionality was similar for self-reported ability to walk ¼ mile (high stable vs. low stable). Among White participants, a higher log IL-6 level was associated numerically with greater odds of being in the low stable vs. high stable cluster (AOR: 1.99, 95 % CI: 0.82, 4.85). Among Black participants, a higher log IL-6 level was associated numerically with lower odds of being in the low stable cluster vs. high stable cluster (AOR: 0.78, 95 % CI: 0.30, 2.00). INTERPRETATION: The association between IL-6 levels and functional trajectories of older adults differed by race. Future analyses exploring stressors faces by other minoritized racial backgrounds are needed to determine the association between IL-6 and functional trajectories. PANEL: RESEARCH IN CONTEXT: Evidence before this study: Previous research has shown that aging is the greatest risk factor for cancer and older adults with cancer experience a higher burden of comorbidities, increasing their risk of functional decline. Race has also been shown to be associated with increased risk for functional decline. Black individuals are exposed to more chronic negative social determinants, compared to White individuals. Previous work has shown that chronic exposure to negative social determinants leads to elevated levels of inflammatory markers, such as IL-6, but studies investigating the relationship between inflammatory markers and functional decline are limited. Added value of this study: Authors of this study sought to understand the association between pre-diagnosis IL-6 levels and functional trajectories post-diagnosis in older adults with cancer, and whether these associations differed between Black and White participants with cancer. Authors decided to utilize the data from the Health, Aging and Body Composition (Health ABC) Study. The Health ACB study was a prospective longitudinal cohort study that has a high representation of Black older adults and collected inflammatory cytokines and physical function data over time. Implications of all available evidence: This work adds to the literature by providing an opportunity to study the difference in the relationships between IL-6 levels and functional trajectories between older Black and White participants with cancer. Identifying factors associated with functional decline and its trajectories may inform treatment decision making and guide development of supportive care interventions to prevent functional decline. Additionally, given the disparities in clinical outcomes for Black individuals, a better understanding of the difference in functional decline based on race will allow more equitable care to be distributed.
背景:炎症标志物如白细胞介素-6(IL-6)的升高与衰老、癌症和功能下降有关。我们评估了老年人癌症患者诊断前 IL-6 水平与诊断后功能轨迹之间的关联。黑人和白人参与者经历不同的社会结构,因此我们试图了解这些关联在黑人和白人参与者之间是否存在差异。
方法:我们对健康老龄化、身体和组成(ABC)前瞻性纵向队列研究进行了二次分析。参与者于 1997 年 4 月至 1998 年 6 月招募。我们纳入了 179 名新诊断癌症且在诊断前 2 年内测量过 IL-6 水平的患者。主要终点是功能测量(自我报告的行走 1/4、20 米步行速度的能力)。非参数纵向模型用于聚类轨迹;多变量和逻辑回归用于建模关联。
结果:平均年龄为 74 岁(标准差 2.9);36%的参与者为黑人。对于自我报告的功能状态,我们确定了 3 个聚类:高稳定、下降、低稳定。对于步态速度,我们确定了 2 个聚类:有弹性、下降。黑人和白人参与者中,聚类轨迹与 IL-6 之间的关系不同(p 交互<0.05)。对于步态速度,在白人参与者中,较高的 log IL-6 水平与更有可能处于下降与有弹性聚类相关[调整后的优势比(AOR):4.31,95%置信区间:1.43,17.46]。在黑人参与者中,较高的 log IL-6 水平与更有可能处于下降与有弹性聚类相关(AOR:0.49,95%置信区间:0.10,2.08)。自我报告的行走 1/4 英里的能力的方向相似(高稳定与低稳定)。在白人参与者中,较高的 log IL-6 水平与更有可能处于低稳定与高稳定聚类相关(AOR:1.99,95%置信区间:0.82,4.85)。在黑人参与者中,较高的 log IL-6 水平与更有可能处于低稳定聚类相关(AOR:0.78,95%置信区间:0.30,2.00)。
结论:老年人癌症患者 IL-6 水平与功能轨迹的关联因种族而异。需要进一步分析探索其他少数族裔面临的压力源,以确定 IL-6 与功能轨迹之间的关系。
面板:研究背景:此前研究表明,衰老最大的风险因素是癌症,癌症老年人的合并症负担更高,增加了他们功能下降的风险。种族也与功能下降的风险增加有关。与白人相比,黑人个体面临更多的慢性负面社会决定因素。之前的研究表明,慢性暴露于负面社会决定因素会导致炎症标志物,如 IL-6,的水平升高,但研究炎症标志物与功能下降之间的关系是有限的。
本研究的新增价值:作者试图了解癌症老年患者诊断前 IL-6 水平与诊断后功能轨迹之间的关系,以及这些关联在黑人和白人癌症患者之间是否存在差异。作者决定利用健康、老龄化和身体组成(健康 ABC)研究的数据。健康 ABC 研究是一项前瞻性纵向队列研究,具有很高的黑人老年人代表性,并且随着时间的推移收集了炎症细胞因子和身体功能数据。
现有全部证据的含义:这项工作通过提供一个机会来研究黑人和白人癌症老年患者之间 IL-6 水平和功能轨迹之间关系的差异,为文献做出了贡献。确定与功能下降及其轨迹相关的因素可以为治疗决策提供信息,并指导开发支持性护理干预措施,以预防功能下降。此外,鉴于黑人个体的临床结果存在差异,更好地了解基于种族的功能下降差异将允许更公平地分配护理。
Cochrane Database Syst Rev. 2022-2-1
J Am Geriatr Soc. 2021-11
JAMA Psychiatry. 2016-5-1
J Gerontol A Biol Sci Med Sci. 2011-6-30
J Cachexia Sarcopenia Muscle. 2021-12
Psychoneuroendocrinology. 2021-1
Tech Innov Patient Support Radiat Oncol. 2020-12
Psychother Psychosom. 2021